Journal of Oncology

Targeted Molecular Therapy in Glioblastoma


Publishing date
01 Aug 2019
Status
Published
Submission deadline
15 Mar 2019

1Universita degli Studi dell'Aquila, L'Aquila, Italy

2Sapienza University of Rome, Rome, Italy

3Gifu University, Gifu, Japan

4Cambridge University Biomedical Innovation Hub, Cambridge, UK


Targeted Molecular Therapy in Glioblastoma

Description

Glioblastoma (GBM) is the most common and malignant type of primary brain tumor. Tumor heterogeneity is a major factor in glioblastoma's poor response to therapy and seemingly inevitable recurrence. The current standard of care for treating newly diagnosed GBMs is maximal safe resection followed by radiation with concurrent and adjuvant temozolomide (Stupp et al., 2005), a regimen which has been shown to improve the median overall survival (12.1 months versus 14.6 months) (Stupp et al., 2005) and the 2-year (27.2% vs. 10.9%) and 5-year (10.9% vs. 1.9%) survival rates compared to radiation alone (Johnson and O'Neill, 2012). There are only four chemotherapeutic agents approved by the Food and Drug Administration (FDA) for treating GBM (lomustine, carmustine, temozolomide, and bevacizumab). Otherwise, multiple randomized phase III clinical trials testing various agents have unfortunately failed to show an improvement in the overall survival of patients with newly diagnosed or recurrent GBM (Seystahl et al., 2016).

This special issue aims to provide a platform for all pharmaceutical and translational scientists and welcomes the submission of original research articles, review articles, and clinical studies focusing on the evaluation of new molecular pathways as pharmacological targets for treatment strategies which may improve the management of aggressive and resistant GBMs.

Potential topics include but are not limited to the following:

  • Mechanisms of resistance to current pharmacological approaches and strategies to overcome the reduced sensitivity
  • Discovery and validation of novel molecular targeted agents
  • Glioma stem-like cells as target for new therapeutic approaches
  • Radio-sensitizing agents
  • Metabolic reprogramming in rapidly growing tumors
  • Immunomodulators and novel immune therapies

Articles

  • Special Issue
  • - Volume 2020
  • - Article ID 5104876
  • - Editorial

Targeted Molecular Therapy in Glioblastoma

Claudio Festuccia | Assunta Leda Biordi | ... | David Bailey
  • Special Issue
  • - Volume 2019
  • - Article ID 9014045
  • - Research Article

A Ploidy Increase Promotes Sensitivity of Glioma Stem Cells to Aurora Kinases Inhibition

Chiara Cilibrasi | Andrèe Guzzi | ... | Angela Bentivegna
  • Special Issue
  • - Volume 2019
  • - Article ID 9043675
  • - Research Article

Live Cell Imaging Supports a Key Role for Histone Deacetylase as a Molecular Target during Glioblastoma Malignancy Downgrade through Tumor Competence Modulation

Aline Menezes | Gustavo Henrique dos Reis | ... | Katia Carneiro
  • Special Issue
  • - Volume 2019
  • - Article ID 1232434
  • - Research Article

Oncosuppressive Role of RUNX3 in Human Astrocytomas

Giedrius Steponaitis | Arunas Kazlauskas | ... | Daina Skiriutė
  • Special Issue
  • - Volume 2019
  • - Article ID 1740763
  • - Review Article

Molecular and Clinical Insights into the Invasive Capacity of Glioblastoma Cells

Carlos Velásquez | Sheila Mansouri | ... | José L. Fernández-Luna
  • Special Issue
  • - Volume 2019
  • - Article ID 9342796
  • - Review Article

Convection-Enhanced Delivery in Malignant Gliomas: A Review of Toxicity and Efficacy

Minghan Shi | Léon Sanche
  • Special Issue
  • - Volume 2019
  • - Article ID 2964783
  • - Review Article

Treatment Strategies Based on Histological Targets against Invasive and Resistant Glioblastoma

Akira Hara | Tomohiro Kanayama | ... | Hiroyuki Tomita
  • Special Issue
  • - Volume 2019
  • - Article ID 1805841
  • - Research Article

The SR-B1 Receptor as a Potential Target for Treating Glioblastoma

Ethan Berney | Nirupama Sabnis | ... | Andras G. Lacko
Journal of Oncology
 Journal metrics
Acceptance rate33%
Submission to final decision93 days
Acceptance to publication48 days
CiteScore3.220
Impact Factor2.600
 Submit